Treatment with APS could significantly decrease the expression levels of Foxp3 and CD4+CD25high on Tregs (P<0.05), and the down-regulatory effect of APS was observed to manifest in a dose-dependent fashion. Here, CD4 is linked to autoimmune polyendocrinopathy.